biostudies-literatureUnknown12(5)Berlanga P<h4>Abstract</h4>MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland, and Spain. At least one genetic alteration leading to a targeted treatment suggestion was identified in 436 patients (69%) with successful sequencing; 10% of these alterations were considered "ready for routine use." Of 356 patients with follow-up beyond 12 months, 107 (30%) received one or more matched targeted therapies-56% of them within early clinical trials-mainly in the AcSé-ESMART platform trial (NCT02813135). Overall, matched treatment resultedCancer discovery1266-1281https://www.ebi.ac.uk/biostudies/studies/S-EPMC9394403biostudies-literatureThe European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.PMC9394403Harttrampf ACLarive ASchleiermacher GLacroix LMichiels SBernard VScoazec JYThebaud EChicard MChevassus CCorradini NBerlanga PGauthier AHladun-Alvaro RAbbou SCotteret SIddir YOwens CVassal GAerts IGeoerger BPierron GSoriano Fernandez AHezam ICasanova MAndre NAdam de Beaumais TMarchais ADelattre OfalseThe European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies.<h4>Abstract</h4>MAPPYACTS (NCT02613962) is an international prospective precision medicine trial aiming to define tumor molecular profiles in pediatric patients with recurrent/refractory malignancies in order to suggest the most adapted salvage treatment. From February 2016 to July 2020, 787 patients were included in France, Italy, Ireland, and Spain. At least one genetic alteration leading to a targeted treatment suggestion was identified in 436 patients (69%) with successful sequencing; 10% of these alterations were considered "ready for routine use." Of 356 patients with follow-up beyond 12 months, 107 (30%) received one or more matched targeted therapies-56% of them within early clinical trials-mainly in the AcSé-ESMART platform trial (NCT02813135). Overall, matched treatment resulted2022-01-01T00:00:00Z2022 May2026-05-28T03:45:42.749Z2025-04-06T00:51:03.189ZS-EPMC93944033529280210.1158/2159-8290.CD-21-1136